HIMS · Hims & Hers Health Inc.
AI read · Good for HIMS
The AI's read
CEO publicly pushed back on the FTC privacy claims and framed regulators as misunderstanding the company’s digital model. He also highlighted Novo dropping its patent suit and promised much lower GLP-1 prices for patients. The FTC suit itself is not new, but the CEO’s on-air defense and explicit pricing guidance are fresh and market-moving. The stock already popped +8.1% and RSI sits at 23.82, so some rebound was likely priced in. We lean bullish. The Novo outcome reduces a headline legal risk and steep price cuts could widen demand, giving the setup asymmetric upside from here.